Compare Amgen, Inc. (AMGN) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Essex Property Trust, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Essex Property Trust, Inc. trades at $293.55 (market cap $18.86B). The key difference: Amgen, Inc. is far larger — about 10.4× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.53%). Which is the better fit depends on your goals.
| AMGN | ESS | |
|---|---|---|
Market Cap | $196.12B | $18.86B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $298.33 |
52-Week Low | $271.18 | $239.61 |
Enterprise Value | $241.41B | $25.59B |
Dividend Yield | 2.77% | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ESS trades at $293.55, up 0.83% on the day, with a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and the company's addition to the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is supported by strong West Coast rental demand and AI-driven employment growth, though risks include high debt levels and Seattle market weakness. Analyst consensus is mixed with a $292.89 price target, slightly below the current price, indicating cautious optimism amid valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
